Table 2.
Baseline clinical status and laboratory parameters (mean ± SD) of patients hospitalized during Delta and Omicron waves with regard to remdesivir (RDV) treatment.
| Delta | Omicron | p (between RDV-Treated Patients in Delta and Omicron Wave) | |||||
|---|---|---|---|---|---|---|---|
| RDV (n = 490) |
NO AVT (n = 680) |
p | RDV (n = 272) |
NO AVT (n = 380) |
p | ||
| CRP, mg/L | 82.5 ± 71.7 | 94.0 ± 84.5 | >0.05 | 67.6 ± 67.6 | 69.9 ± 78.9 | >0.05 | <0.001 |
| PCT, ng/mL | 0.4 ± 1.3 | 1.1 ± 8.3 | >0.05 | 0.9 ± 3.1 | 1.8 ± 9.2 | >0.05 | >0.05 |
| WBC, ×103/µL | 7.0 ± 6.5 | 7.1 ± 3.9 | 0.006 | 7.8 ± 8.0 | 8.0 ± 4.9 | >0.05 | 0.003 |
| Lymphocytes, ×103/µL | 1.4 ± 4.7 | 1.1 ± 1.4 | >0.05 | 1.3 ± 1.8 | 1.2 ± 1.5 | >0.05 | 0.01 |
| Neutrophils, ×103/µL | 5 ± 3.4 | 5.3 ± 3.2 | 0.008 | 5.5 ± 4.7 | 6.1 ± 6.0 | >0.05 | >0.05 |
| Platelets, ×103/µL | 185.5 ± 79.5 | 213.0 ± 96.0 | <0.001 | 202.4 ± 93.2 | 212.8 ± 101.5 | 0.04 | 0.006 |
| IL-6, pg/mL | 102.9 ± 329.1 | 122.4 ± 383.1 | >0.05 | 160.3 ± 611.8 | 218.2 ± 1399.5 | 0.006 | >0.05 |
| d-dimer, ng/mL | 1904.9 ± 5909.8 | 2165.4 ± 4917.6 | 0.004 | 2282.4 ± 4918.7 | 2809.6 ± 8179.5 | >0.05 | 0.03 |
| ALT, IU/L | 42.5 ± 40.6 | 47.8 ± 51.1 | >0.05 | 34.9 ± 31.6 | 45.3 ± 96.3 | >0.05 | <0.001 |
| Stable symptomatic, SpO2 > 95% or asymptomatic | 12.0 (59) | 14.3 (97) | >0.05 | 27.9 (76) | 34.7 (132) | >0.05 | <0.001 |
| Unstable symptomatic, SpO2 ≤ 95% or ARDS | 87.9 (431) | 85.9 (579) | >0.05 | 72.1 (196) | 65.5 (248) | >0.05 | <0.001 |
Abbreviations: AVT, antiviral therapy; ALT, alanine aminotransferase; ARDS, acute respiratory distress syndrome; CRP, C-reactive protein; IL-6, interleukin-6; PCT, procalcitonin; RDV, remdesivir; SD, standard deviation; SpO2, saturation of peripheral oxygen; WBC, white blood cells.